Prevalence and Mortality of Sarcopenia in a Community-dwelling Older Japanese Population: The Hisayama Study.


Journal

Journal of epidemiology
ISSN: 1349-9092
Titre abrégé: J Epidemiol
Pays: Japan
ID NLM: 9607688

Informations de publication

Date de publication:
05 May 2021
Historique:
pubmed: 9 6 2020
medline: 1 9 2021
entrez: 9 6 2020
Statut: ppublish

Résumé

The prevalence of sarcopenia defined using the Asian Working Group for Sarcopenia (AWGS) criteria in Asian communities has not been fully addressed. Moreover, few studies have addressed the influence of sarcopenia on mortality. A total of 1,371 and 1,597 residents aged 65 years or older participated in health surveys in 2012 and 2017. Sarcopenia was determined using the AWGS definition. Factors associated with the presence of sarcopenia were assessed using a logistic regression model in participants in the 2012 survey. Subjects in the 2012 survey were followed-up prospectively for a median of 4.3 years. Mortality risk for subjects with sarcopenia was examined using the Cox proportional hazards model. The crude prevalence of sarcopenia was 7.4% and 6.6% in participants at the 2012 and 2017 surveys, respectively; there was no significant difference between surveys (P = 0.44). The prevalence of sarcopenia increased significantly with age in both sexes (both P for trend <0.001). Subjects with sarcopenia were more likely to exercise less regularly, to intake less total energy, and to exhibit a disability in activity of daily living than those without. The multivariable-adjusted hazard ratio for all-cause mortality was 2.20 (95% confidence interval, 1.25-3.85) in subjects with sarcopenia, compared to those without. Approximately 7% of older subjects had sarcopenia in a community-dwelling older Japanese population. Moreover, subjects with sarcopenia had an increased mortality risk. Our findings suggest that a public health strategy for sarcopenia is needed to extend healthy life expectancy.

Sections du résumé

BACKGROUND BACKGROUND
The prevalence of sarcopenia defined using the Asian Working Group for Sarcopenia (AWGS) criteria in Asian communities has not been fully addressed. Moreover, few studies have addressed the influence of sarcopenia on mortality.
METHODS METHODS
A total of 1,371 and 1,597 residents aged 65 years or older participated in health surveys in 2012 and 2017. Sarcopenia was determined using the AWGS definition. Factors associated with the presence of sarcopenia were assessed using a logistic regression model in participants in the 2012 survey. Subjects in the 2012 survey were followed-up prospectively for a median of 4.3 years. Mortality risk for subjects with sarcopenia was examined using the Cox proportional hazards model.
RESULTS RESULTS
The crude prevalence of sarcopenia was 7.4% and 6.6% in participants at the 2012 and 2017 surveys, respectively; there was no significant difference between surveys (P = 0.44). The prevalence of sarcopenia increased significantly with age in both sexes (both P for trend <0.001). Subjects with sarcopenia were more likely to exercise less regularly, to intake less total energy, and to exhibit a disability in activity of daily living than those without. The multivariable-adjusted hazard ratio for all-cause mortality was 2.20 (95% confidence interval, 1.25-3.85) in subjects with sarcopenia, compared to those without.
CONCLUSIONS CONCLUSIONS
Approximately 7% of older subjects had sarcopenia in a community-dwelling older Japanese population. Moreover, subjects with sarcopenia had an increased mortality risk. Our findings suggest that a public health strategy for sarcopenia is needed to extend healthy life expectancy.

Identifiants

pubmed: 32507775
doi: 10.2188/jea.JE20190289
pmc: PMC8021883
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

320-327

Références

Osteoporos Int. 2014 Mar;25(3):1081-8
pubmed: 24146097
J Nutr Health Aging. 2008 Aug-Sep;12(7):433-50
pubmed: 18615225
J Clin Epidemiol. 1989;42(8):703-9
pubmed: 2760661
Geriatr Gerontol Int. 2017 Oct;17(10):1642-1647
pubmed: 28261905
Geriatr Gerontol Int. 2014 Feb;14 Suppl 1:69-75
pubmed: 24450563
Circulation. 2013 Sep 10;128(11):1198-205
pubmed: 23902756
J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):312-21
pubmed: 27239412
Arch Gerontol Geriatr. 2009 Jul-Aug;49(1):118-22
pubmed: 18621426
Age Ageing. 2014 Nov;43(6):748-59
pubmed: 25241753
Osteoporos Int. 2017 Jan;28(1):189-199
pubmed: 27885410
J Gerontol A Biol Sci Med Sci. 2014 Apr;69(4):438-46
pubmed: 24085400
J Am Med Dir Assoc. 2015 Mar;16(3):247-52
pubmed: 25548028
Public Health Nutr. 2016 Dec;19(17):3178-3184
pubmed: 27406257
Geriatr Gerontol Int. 2013 Oct;13(4):958-63
pubmed: 23452074
Circulation. 2008 Dec 16;118(25):2672-8
pubmed: 19106389
Can Fam Physician. 2014 May;60(5):e272-80
pubmed: 24829022
J Am Med Dir Assoc. 2014 Feb;15(2):95-101
pubmed: 24461239
J Hypertens. 2007 Jun;25(6):1105-87
pubmed: 17563527
J Nutr Health Aging. 2014 Mar;18(3):284-90
pubmed: 24626756
Neurology. 2017 May 16;88(20):1925-1932
pubmed: 28424272
Am J Epidemiol. 1998 Apr 15;147(8):755-63
pubmed: 9554417
J Gerontol A Biol Sci Med Sci. 2016 Apr;71(4):529-35
pubmed: 26286608
J Gerontol A Biol Sci Med Sci. 2016 Feb;71(2):259-64
pubmed: 26333772
Med Care. 2015 Apr;53(4):346-54
pubmed: 25719432
J Nutr Health Aging. 2014 May;18(5):547-53
pubmed: 24886743
J Am Med Dir Assoc. 2013 Dec;14(12):911-5
pubmed: 24094646
Age Ageing. 2010 Jul;39(4):412-23
pubmed: 20392703
Geriatr Gerontol Int. 2014 Feb;14 Suppl 1:46-51
pubmed: 24450560
Stroke. 2003 Oct;34(10):2333-8
pubmed: 12958329
PLoS One. 2017 Jan 17;12(1):e0169548
pubmed: 28095426
Int Psychogeriatr. 1997;9 Suppl 1:65-9
pubmed: 9447429
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
J Diabetes Metab Disord. 2017 May 16;16:21
pubmed: 28523252
Exp Gerontol. 2015 Sep;69:103-10
pubmed: 25979160
Diabet Med. 1998 Jul;15(7):539-53
pubmed: 9686693
Stroke. 2000 Apr;31(4):811-6
pubmed: 10753980
J Am Med Dir Assoc. 2015 Nov 1;16(11):1003.e1-6
pubmed: 26385304
J Epidemiol. 2003 Sep;13(5):251-8
pubmed: 14604220

Auteurs

Kimitaka Nakamura (K)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University.

Daigo Yoshida (D)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.

Takanori Honda (T)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.

Jun Hata (J)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.
Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University.

Mao Shibata (M)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.
Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University.

Yoichiro Hirakawa (Y)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.

Yoshihiko Furuta (Y)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.

Hiro Kishimoto (H)

Faculty of Arts and Science, Kyushu University.

Tomoyuki Ohara (T)

Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University.

Takanari Kitazono (T)

Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University.
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University.

Yasuharu Nakashima (Y)

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University.

Toshiharu Ninomiya (T)

Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University.
Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH